Novo Nordisk Divides R&D, Expects More Late-Stage Studies In 2021
CSO To Retire, And Rybelsus Sales Grow
Novo Nordisk’s newer GLP1 products for diabetes, Ozempic and Rybelsus, drove the company’s sales growth in 2020, and with its CSO retiring after a two-decade shift, internal appointments are made to lead a reorganized R&D function.
